Empagliflozin in non alcoholic fatty liver

Investigating the effect of empagliflozin on patients with non alcoholic fatty liver diseases

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150706023084N18

Enrollment

Registered

2023-09-02

Start date

2023-08-11

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patient with non alcoholic fatty liver. Other specified inflammatory liver diseases

Interventions

Intervention group : The case group are 30 patient with diabetic and non alcoholic fatty liver with treatment by empagliflozin in 3 month and then investigating of the result of empagliflozin by fatty

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic patient Fatty liver Empagliflozin

Exclusion criteria

Exclusion criteria: Drug use for fatty liver

Design outcomes

Primary

Measure	Time frame
Different grades of fatty liver. Timepoint: Before the intervention and 30 days after it, the question paper and sonography and fibroscan analysis data will be evaluated. Method of measurement: Investigating of sonography(fibroscan).	—

Secondary

Measure	Time frame
Investigating sonography related to the course of recovery during treatment. Timepoint: From the beginning of treatment for 3 month. Method of measurement: Examining the sonography of the patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMobina shieh

Islamic Azad University

mobinashieh123@gmail.com+98 21 6659 6099

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026